Hearing Loss Trial, Recruiting NCT05312983 Sponsor: Institut Pasteur Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT05312983
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For all participants:

  • People who are over 18 years old
  • People who are covered by a social security system
  • People who have a good understanding of French, both spoken and written

For the group with age-related hearing loss (anticipated presbycusis):

  • People over 40 who currently use a hearing aid or are getting one for the first time
  • People between 18 and 40 who currently use a hearing aid, are getting one for the first time, or have a progressive genetic hearing condition present from birth

For healthy volunteers:

  • People who have no known hearing loss

Who may not be able to join:

  • People who have been regularly exposed to loud sounds over a long period of time
  • People who have a history of exposure to substances known to damage hearing
  • People who have lasting effects from ear infections, or a history of ear, nose, or throat conditions that permanently affect hearing or balance
  • People whose ethnic background is one for which the Pasteur Institute does not have data on the specific genes being studied (confirm with trial site)
  • People who have type 2 diabetes
  • People who have a neurological or psychiatric condition that affects their understanding or ability to move
  • People who are under legal guardianship
  • People whose freedom is restricted by a court or government decision, or who are under legal protection
  • People who are not covered by a social security system
  • People who are taking narcotics, alcohol, or medications that reduce cognitive abilities

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Avan, MD, CERIAH

Phone: +33 (0)1 76 53 50 29

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Pasteur
Registry
ClinicalTrials.gov
Start date
28 July 2022
Est. completion
31 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Measurement of specificity and sensitivity of the audiological test battery in participants with early-onset presbycusis after identification of pathogenic variants by sequencing and division into subgroups.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov